| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 35(3); 2003 > Article
Cancer Research and Treatment 2003;35(3): 245-253. doi: https://doi.org/10.4143/crt.2003.35.3.245
Clinical Features of Pulmonary Large Cell Neuroendocrine Carcinoma
Moo Suk Park, Kil Dong Kim, Jae Ho Chung, Dong Hwan Shin, Kyung Young Chung, Joo Hang Kim, Chang Yul Lee, Young Sam Kim, Hyung Joong Kim, Se Kyu Kim, Chul Min Ahn, Sung Kyu Kim, Joon Chang
1Department of Internal Medicine, Yonsei University Collegeof Medicine, Seoul, Korea. chang@yumc. yonsei.ac.kr
2Department of Cardiovascular and Thoracic Surgery, YonseiUniversity College of Medicine, Seoul, Korea.
3Department of Pathology, Yonsei University College ofMedicine, Seoul, Korea.
4The Institute of Chest Diseases, Yonsei University Collegeof Medicine, Seoul, Korea.
5Brain Korea 21 Project for Medical Sciences, YonseiUniversity College of Medicine, Seoul, Korea.
  Published online: June 30, 2003.
This study was performed to investigate the clinical features of large cell neuroendocrine carcinomas (LCNEC).
We retrospectively reviewed the histopathology and clinical information of 37 patients with LCNEC, diagnosed between June 1992 and May 2002 at the Severance Hospital, and performed immunohistochemical (IHC) staining.
The prevalence of LCNEC among primary lung cancers was 0.3%, 37 out of 13, 012 cases over a 10 year period. The mean age was 61+/-12 years old, with 34 (92%) males and 3 (8%) females. 30 patients smoked, with an average of 42 packs per year. A cough was the most frequent symptom. The tumor was located at the periphery of the lung in 24 cases (65%). Among the 30 cases that underwent surgery, 4 were diagnosed pathological stage IA, 11 IB, 1 IIB, 13 IIIA and 1 IIIB. The 7 clinically non-operable cases were IIIB in 3, and IV in 4. The positive rates of CD56, thyroid transcription factor-1 (TTF-1), chromogranin A, synaptophysin and 34betaE12 for tumor cells were 88.9, 55.6, 42.1, 31.6 and 21.1%, respectively, from the IHC staining. The median survival time and 5 year-survival rate were 24 months and 27%, respectively. The group that underwent surgery had a better prognosis than those that did not.
The positive rates for the tumor markers varied, but those of the CD56 and TFT-1 were the highest. The possibility of LCNEC needs to be evaluated for the following situations: small cell carcinomas located at the periphery and not responding chemotherapy, small cell carcinomas diagnosed by percutaneous needle aspiration, poorly differentiated non-mall cell carcinomas, with uncertain histologic type, and unclassified neuroendocrine tumor, etc.
Key words: Lung neoplasm;Large cell;Carcinoma;Neuroendocrine tumor
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI